Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atazanavir + ritonavir + rabeprazole + betaine hydrochloride
- Development stage
- Phase 1
- Lead developer
- AbbVie
- Modality
- Drug Delivery Systems
- Administration
- Oral
01
Overview
This is a combination of four agents studied in research settings to investigate and potentially counteract the drug-drug interaction between rabeprazole (a proton pump inhibitor) and atazanavir/ritonavir (an antiretroviral medication combination). Atazanavir/ritonavir is used to treat HIV infection. Rabeprazole significantly reduces gastric acid, which impairs the absorption of atazanavir, as it requires an acidic environment for optimal uptake. Betaine hydrochloride has been explored as a potential agent to re-acidify the stomach and restore atazanavir absorption when co-administered with rabeprazole. Studies have shown that rabeprazole substantially decreases atazanavir exposure (around 70%). The addition of betaine hydrochloride in these studies only partially restored atazanavir levels (approximately 12-13% restoration). This specific four-drug combination is not a commercially available product but represents a research approach to managing complex drug interactions in patient care.
- Other names
- atazanavir/ritonavir + rabeprazole + betaine hydrochloride
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)PR (Progesterone receptor)CYP3A7 (Cytochrome P450 3A7)
Beyond the preview
Go deeper on atazanavir + ritonavir + rabeprazole + betaine hydrochloride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atazanavir + ritonavir + rabeprazole + betaine hydrochloride.